As RSV season approaches, many parents ask: does my baby need RSV protection this year—and who needs it again in the second season? New American Academy of Pediatrics (AAP) guidance for 2026–2027 keeps protection for all young infants and expands who qualifies for immunization at 8–19 months.
What is RSV?
RSV (respiratory syncytial virus) spreads through the air and close contact. In most people it feels like a mild cold. In babies it can inflame the tiny airways (bronchiolitis) or the lungs (pneumonia). In the United States, RSV is a leading cause of infant hospitalization—about 50,000–80,000 hospital stays a year in children under five, per the CDC. Those are U.S. figures; local patterns differ, but very young babies can still get seriously unwell.
First RSV season: all infants under 8 months
The AAP still recommends RSV immunization for all infants under 8 months born during or entering their first RSV season—unless the baby already has documented protection from vaccination of their pregnant parent (maternal RSVpreF vaccine). Baby options are long-acting antibody shots: nirsevimab and clesrovimab (ready-made antibodies, not a traditional vaccine that trains the baby’s own immune system).
The AAP has no preference between nirsevimab and clesrovimab for the first season, and no preference between infant immunization and maternal vaccination when either path is available. See HealthyChildren.org and AAP News (2 Sep 2026); the full policy appears in November 2026 Pediatrics.
What’s new: second-season high-risk expansion
For ages 8–19 months entering a second RSV season, immunization is for higher-risk children only. Only nirsevimab is approved then. Newly expanded high-risk groups include:
- preterm birth before 32 weeks, whether or not the child still needs medicines or oxygen;
- hemodynamically significant congenital heart disease (a heart defect that causes symptoms or strains the heart);
- lung anatomy differences or neuromuscular conditions that raise severe-RSV risk;
- Down syndrome or other chromosomal differences linked to higher severe-RSV risk.
Earlier categories still count—such as chronic lung disease of prematurity needing support in the six months before the second season, severe immunocompromise, and certain cystic fibrosis cases. Ask your paediatrician which applies.
Timing and India
Babies born shortly before or during the season are ideally immunized in the first week of life, often in the birth hospital. Outside the season, protection is given shortly before or early in the season. In India, product stock and national advice may differ from U.S. AAP schedules—ask what RSV options exist locally (IAP/clinic availability). Do not assume every product is universally stocked.
What parents can do
- Ask whether first-season RSV immunization—or documented maternal vaccination—is already covered.
- If your child is 8–19 months and was very preterm, or has significant heart/lung issues, a neuromuscular condition, or Down syndrome, ask about second-season nirsevimab.
- Hand hygiene, no smoke exposure, and limiting contact with people who have colds still help when babies are tiny.
- For personalised timing, you can book an appointment with Dr. Vannala Raju.
When to seek care
Seek urgent care for fast or laboured breathing, chest indrawing, bluish lips, pauses in breathing, poor feeding, unusual sleepiness, or fever in a young infant. Mild sniffles can often be watched with clinician advice; breathing trouble is never “wait and see.”
This article is for general parent information based on published AAP and CDC guidance. It is not a substitute for personal medical advice for your child. RSV product availability and national schedules in India may differ from U.S. AAP recommendations.
Sources: HealthyChildren.org — AAP RSV immunization 2026–2027; AAP News — second-season high-risk expansion; CDC — RSV overview.
Leave a Reply